Zydus Lifesciences shares hit a 52-week high of Rs 1,266.60, then fell as Q2 profit dropped 26.6% to Rs 925.50 crore even as sales rose 29%.

Zydus Lifesciences Limited told exchanges on 4 November that its consolidated net profit for the July to September quarter fell to Rs 925.50 crore.

A year earlier, the drugmaker had earned Rs 1,260.90 crore. Sales kept climbing. Revenue from operations jumped 29% to about Rs 7,910 crore from Rs 6,123 crore.

Operating profit moved the other way, slipping 6% to Rs 1,895 crore, and its margin narrowed to 23.95% from 32.9%.

In simple terms, the company sold a lot more but kept less of each rupee.

Growth came from all three big markets. North America brought in Rs 3,315 crore, up 21%.

The India business earned Rs 1,884 crore, up 18%, and international markets added Rs 1,001 crore, up 33%.

Managing Director Sharvil Patel pointed to ‘strong, all-round momentum’ in the company’s branded businesses.

Zydus also spent Rs 657.30 crore on research, which is 8.3% of its revenue. The results filing also noted two settlements.

Zydus Worldwide DMCC received Rs 146.80 crore, about $15.5 million, after settling a dispute with Teva.

The company also agreed to pay Astellas Pharma $120 million, made up of $45 million in one-time costs and $75 million in licensing fees.

Over the first six months of the year, profit fell 30.9% to Rs 1,885.90 crore from Rs 2,727.70 crore.

Separately, the US FDA inspected the company’s Moraiya plant near Ahmedabad from 5 to 13 October, and the visit closed with five observations.

At 13:40 pm, Zydus Lifesciences shares were trading at Rs 1,197.20 on NSE, down by 3.50% from the previous close of Rs 1,240.60.

It’s still up 30.73% in 2026, and the company’s market value is Rs 1,19,321.41 crore.

Want to look beyond tips and market noise? Explore market sentiment, money flows and research-backed trade ideas—all in one app. Download Intraday Traders by EquityPandit and stay informed.